Shares of Shukra Pharmaceuticals Limited rose nearly 2% to ₹19.57 today after the company announced the opening of four new branch offices in major Indian cities — Mumbai, Gurgaon (NCR), Bangalore, and Kolkata — as part of its strategic growth plan.
In a regulatory filing dated July 9, 2025, the company said the expansion aligns with its vision of delivering quality pharmaceutical solutions across India and strengthening ties with institutional and healthcare stakeholders.
Key goals of the expansion:
-
To tap into high-potential regional markets.
-
To participate more actively in tenders from Government, Semi-Government, and Private sector bodies.
-
To build closer relationships with institutional clients, procurement agencies, and healthcare stakeholders.
The company expects the new offices to enhance business development, unlock growth opportunities, improve operational efficiency, and create long-term value for shareholders.
Shukra Pharmaceuticals also reiterated its commitment to transparency and assured stakeholders that all material updates will continue to be disclosed promptly.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor before making investment decisions.
